Trial · NCT00415506
Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation
NCT00415506, Phase 1, Phase 2, Completed, Oregon Health and Science University; results first posted 2013-08-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation. Trials, record NCT00415506. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00415506
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation
- NCT number
- NCT00415506
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 20 participants, actual
- Lead sponsor
- Oregon Health and Science University
- Conditions
- Scleritis, Orbital Disease
- Interventions
- Rituximab
- First posted
- 2006-12-25
- Last updated
- 2013-08-16
- Results first posted
- 2013-08-08
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Reduction of Medications | 24 Weeks | Reduction (decrease in dosage) of systemic corticosteroids or immunosuppressive therapy by at least 50% by 24 weeks. |
| Primary | Improved Control of Inflammation | 24 weeks | For patients with scleritis, disease activity as measured by a modified grading system first described by McCluskey et al. (McCluskey and Wakefield 1987; McCluskey and Wakefield 1991). Improvement in scleritis activity will be defined as a reduction in this grading score of 2 or more, or an overall score of 4 or less by 24 weeks. For patients with orbital inflammation, disease activity as measured by a modified grading system first devised by Werner (Werner 1977). Improvement in orbital inflammation will be defined as a reduction in this grading score of 2 or more, or an overall score of 3 or less. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Reduction of Medications | 24 Weeks | Only patients currently on systemic corticosteroids were analyzed for this outcome point. | participants | NUMBER |
| PRIMARY | Improved Control of Inflammation | 24 weeks | participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Reduction of Medications | Scleritis | 5 | participants | ||
| Reduction of Medications | Orbital Inflammation | 4 | participants | ||
| Improved Control of Inflammation | Scleritis | 9 | participants | ||
| Improved Control of Inflammation | Orbital Inflammation | 7 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Scleritis | 12 | |
| Overall Study | STARTED | Orbital Inflammation | 10 | |
| Overall Study | COMPLETED | Scleritis | 9 | |
| Overall Study | COMPLETED | Orbital Inflammation | 9 | |
| Overall Study | NOT COMPLETED | Scleritis | 3 | |
| Overall Study | NOT COMPLETED | Orbital Inflammation | 1 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Orbital Inflammation | ||
| Total, all-cause mortality | Scleritis | ||
| Total, other adverse events | Orbital Inflammation | 0 | 10 |
| Total, other adverse events | Scleritis | 0 | 12 |
| Total, serious adverse events | Orbital Inflammation | 0 | 10 |
| Total, serious adverse events | Scleritis | 0 | 12 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 24652467 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Scleritis vs Orbital Inflammation: Reduction of Medications | Trial comparisons |
| Scleritis vs Orbital Inflammation: Improved Control of Inflammation | Trial comparisons |
| Orbital Inflammation vs Scleritis: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00415506
GET https://conductscience.org/api/trials/v1/NCT00415506/registered